SG10202008673WA - Method of treating cancer associated with a ras mutation - Google Patents

Method of treating cancer associated with a ras mutation

Info

Publication number
SG10202008673WA
SG10202008673WA SG10202008673WA SG10202008673WA SG10202008673WA SG 10202008673W A SG10202008673W A SG 10202008673WA SG 10202008673W A SG10202008673W A SG 10202008673WA SG 10202008673W A SG10202008673W A SG 10202008673WA SG 10202008673W A SG10202008673W A SG 10202008673WA
Authority
SG
Singapore
Prior art keywords
treating cancer
cancer associated
ras mutation
ras
mutation
Prior art date
Application number
SG10202008673WA
Inventor
Lan Huang
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56878960&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202008673W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of SG10202008673WA publication Critical patent/SG10202008673WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10202008673WA 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation SG10202008673WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129654P 2015-03-06 2015-03-06
US201562249788P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
SG10202008673WA true SG10202008673WA (en) 2020-10-29

Family

ID=56878960

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707127VA SG11201707127VA (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation
SG10202008673WA SG10202008673WA (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201707127VA SG11201707127VA (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation

Country Status (16)

Country Link
US (4) US10238650B2 (en)
EP (1) EP3265090A4 (en)
JP (1) JP6769982B2 (en)
KR (1) KR102626155B1 (en)
CN (1) CN107530341B (en)
AU (2) AU2016229294B2 (en)
BR (1) BR112017018954A2 (en)
CA (1) CA2978567A1 (en)
CL (1) CL2017002241A1 (en)
HK (2) HK1250008A1 (en)
IL (1) IL254256A0 (en)
MX (1) MX2017011374A (en)
MY (1) MY190034A (en)
RU (1) RU2736045C2 (en)
SG (2) SG11201707127VA (en)
WO (1) WO2016144635A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229295B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
MX2017011374A (en) 2015-03-06 2018-01-23 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation.
KR20180027563A (en) 2015-07-13 2018-03-14 비욘드스프링 파마수티컬스, 인코포레이티드. Flinabuled composition
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20190015361A (en) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. Compositions and methods for reducing neutropenia
JP2020503363A (en) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Tubulin binding compounds and their therapeutic use
JP2020514412A (en) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Methods for reducing neutropenia
JP2019019094A (en) * 2017-07-19 2019-02-07 学校法人福岡大学 Mutant kras-related signal inhibitory composition
CN109498627B (en) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 Pharmaceutical composition for treating tumors and application thereof
CN112135614A (en) * 2018-01-24 2020-12-25 大连万春布林医药有限公司 Compositions and methods for reducing thrombocytopenia by administering plinabulin
US11723891B2 (en) 2018-04-12 2023-08-15 Umc Utrecht Holding B.V. Drug combinations for use in the treatment of RAS-mutant cancer
CN112543636B (en) * 2018-06-01 2024-03-01 大连万春布林医药有限公司 Compositions and methods for treating cancers associated with EGFR mutations
CN109652535A (en) * 2019-01-30 2019-04-19 上海安甲生物科技有限公司 Identify human thyroid tubercle good pernicious kit and its application method and application
KR102222693B1 (en) * 2019-04-04 2021-03-04 금정제약 주식회사 Novel uses of H-REV107 derived peptide
CN114728005A (en) 2019-11-28 2022-07-08 应世生物科技(南京)有限公司 Use of BI853520 in cancer treatment
CN111534599A (en) * 2020-06-18 2020-08-14 重庆浦洛通基因医学研究院有限公司 Thyroid cancer auxiliary molecular diagnosis kit and using method thereof
WO2022216908A1 (en) * 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CA3234699A1 (en) * 2021-10-07 2023-04-13 Beyondspring Pharmaceuticals, Inc. Methods for treating cancers and tumors
WO2024006678A1 (en) * 2022-06-26 2024-01-04 Biohaven Therapeutics Ltd. Methods of treating glioblastoma with prodrugs of riluzole
CN117919234A (en) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 Application of naphthalamide compound in treatment of drug-resistant tumor
CN117919235A (en) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 Application of naphthalamide compound in treating KRAS mutation related diseases

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164B1 (en) 1970-12-29 1975-04-10
MW2380A1 (en) 1979-06-29 1982-03-10 Wellcome Found Pharmaceutical ethers,preparation,use and intermediates therefor and their preparation
DK160866C (en) 1980-12-18 1991-10-14 Wellcome Found METHOD OF ANALOGUE FOR THE PREPARATION OF PHENOLETHER COMPOUNDS
JPS58167304A (en) 1982-03-24 1983-10-03 松下電器産業株式会社 Refuse disposal plant
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (en) 1990-10-31 1993-10-05 Toray Ind Inc Medicine for thrombocytopenia
JPH059164A (en) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd Production of optically active mandelonitrile derivative
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
SG48993A1 (en) 1992-10-01 1998-05-18 Wellcome Found Immunopotentiatory agent and physiologically acceptable salts thereof
WO1994012031A1 (en) 1992-11-27 1994-06-09 Napro Biotherapeutics, Inc. Injectable composition
JPH0725858A (en) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd Piperazine derivative
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (en) 1996-09-04 2001-02-05 新日本製鐵株式会社 Novel antitumor substance, microorganism and method for producing the substance, and cell cycle inhibitor and antitumor agent containing the substance as active ingredient
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
US6479484B1 (en) 1997-11-21 2002-11-12 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
KR20010034469A (en) 1998-01-29 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 Method for preparing an N-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
PL343249A1 (en) 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (en) 1998-10-23 2002-09-20 Adir NOVEL DIHYDRO AND TETRAHYDROQUINOLEINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
ATE353365T1 (en) 1999-08-23 2007-02-15 Dana Farber Cancer Inst Inc NEW B7-4 MOLECULES AND THEIR USES
JP4896327B2 (en) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド PD-1, B7-4 receptors and uses thereof
CA2392477A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
BR0017067A (en) 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Cell division inhibitor, dehydrogenase, method for producing a cell division and compound inhibitor
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
DE60137037D1 (en) 2000-05-09 2009-01-29 Angiorx Corp Piperazine CONNECTIONS
EP1345938A1 (en) 2000-12-28 2003-09-24 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) * 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
KR20050000544A (en) 2002-05-17 2005-01-05 아방티 파르마 소시에테 아노님 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
CA2494049C (en) 2002-08-02 2011-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
SE0202429D0 (en) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1711487A1 (en) 2004-02-04 2006-10-18 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EA010198B1 (en) 2004-04-19 2008-06-30 Крка, Товарна Здравил, Д.Д., Ново Место Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
DE202004018940U1 (en) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Snap closure, snap-fastener tape and resealable bag
SI2439273T1 (en) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101248089A (en) 2005-07-01 2008-08-20 米德列斯公司 Human monoclonal antibodies to programmed death ligand 1(PD-L1)
EP1926724A1 (en) 2005-09-21 2008-06-04 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP2009523813A (en) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Specific therapies using integrin ligands to treat cancer
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP5755839B2 (en) 2007-02-15 2015-07-29 マンカインド コーポレイション Method for enhancing T cell response
WO2008128169A1 (en) 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
US20090170837A1 (en) * 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2227296B1 (en) 2008-01-08 2015-11-25 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
UY31952A (en) 2008-07-02 2010-01-29 Astrazeneca Ab 5-METHYLIDENE-1,3-THIAZOLIDINE-2,4-DIONAS REPLACED AS PIM QUINASE INHIBITORS
UA109108C2 (en) 2008-12-09 2015-07-27 Дженентек, Інк. Anti-pd-ll antibody and its use to enhance t-cell function
EA023344B1 (en) 2009-01-16 2016-05-31 Тева Фармасьютикал Индастриз Лтд. Method for treating or preventing neutropenia or leukopenia or decreasing the incidence of infection as manifested by febrile neutropenia
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CA2770397A1 (en) 2009-08-10 2011-02-17 Board Of Regents, The University Of Texas System Treatment of astrocytes-tumor cells with inhibitors of endothelin receptors
US20110160159A1 (en) 2009-09-15 2011-06-30 John Ryan Treatment of cancer
CA2778707A1 (en) 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
ES2646863T3 (en) 2009-11-24 2017-12-18 Medimmune Limited B7-H1 specific binding agents
CN101766815B (en) 2009-12-31 2012-04-25 胡松华 Application of taxol and taxotere
US20130225424A1 (en) * 2010-03-03 2013-08-29 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
US20130131018A1 (en) 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (en) 2010-07-28 2012-02-16 Fuji Electric Co Ltd Thin film solar cell and method for manufacturing the same
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2012074904A2 (en) 2010-11-29 2012-06-07 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (en) 2011-01-07 2013-02-21 Univ China Medical Pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells and uses of the same
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
JP2014533955A (en) 2011-11-28 2014-12-18 ナショナル リサーチ カウンシル オブ カナダ Paclitaxel-responsive cancer marker
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
CA3122808A1 (en) 2012-05-09 2013-11-14 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
US10034939B2 (en) 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
DK2958943T3 (en) 2013-02-20 2019-12-09 Univ Pennsylvania Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
JP2016520643A (en) 2013-06-03 2016-07-14 ノバルティス アーゲー Combination of anti-PD-L1 antibody and MEK inhibitor and / or BRAF inhibitor
CN105705148B (en) * 2013-10-11 2021-03-23 大连万春布林医药有限公司 Cancer therapy using a combination of plinabulin and a taxane
JP2016540042A (en) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド Combinations of checkpoint inhibitors and therapeutics to treat cancer
JP6657105B2 (en) 2013-11-06 2020-03-04 アメリカ合衆国 Methods for subtyping lymphoma types by expression profiling
CN104796448B (en) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 The data processing method and device of network system
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
RU148945U1 (en) 2014-07-29 2014-12-20 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) CONVECTIVE BOILER UNIT
JP6698084B2 (en) 2014-08-08 2020-05-27 オンコクエスト インコーポレイテッドＯｎｃｏｑｕｅｓｔ Ｉｎｃ． Tumor antigen-specific antibodies and TLR3 stimulation to improve the outcome of cancer checkpoint interference therapy
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
MX2017010338A (en) 2015-02-12 2017-12-20 Beyondspring Pharmaceuticals Inc Use of plinabulin in combination with immune checkpoint inhibitors.
AU2016229295B2 (en) * 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
MX2017011374A (en) * 2015-03-06 2018-01-23 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation.
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (en) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 Deuterated dehydrophenylahistin class compound and preparation method thereof and preparing the application in anti-tumor drug
KR20180027563A (en) 2015-07-13 2018-03-14 비욘드스프링 파마수티컬스, 인코포레이티드. Flinabuled composition
WO2017062505A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20190015361A (en) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. Compositions and methods for reducing neutropenia
JP2020503363A (en) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Tubulin binding compounds and their therapeutic use
JP2020514412A (en) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Methods for reducing neutropenia
ES2942889T3 (en) 2017-03-13 2023-06-07 Beyondspring Pharmaceuticals Inc Plinabulin compositions and use thereof
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
CN112135614A (en) 2018-01-24 2020-12-25 大连万春布林医药有限公司 Compositions and methods for reducing thrombocytopenia by administering plinabulin
NZ766454A (en) 2018-02-01 2024-02-23 Beyondspring Pharmaceuticals Inc Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
CN110240592A (en) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (Z) -3- (3- formoxyl benzylidene) piperazinedione compounds and its application in preparation of anti-tumor drugs
CN111936143A (en) 2018-04-05 2020-11-13 诺维嘉研究公司 Novel combination of tubulin polymerization inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of cancer
CN112543636B (en) 2018-06-01 2024-03-01 大连万春布林医药有限公司 Compositions and methods for treating cancers associated with EGFR mutations
CN112638388A (en) 2018-08-16 2021-04-09 大连万春布林医药有限公司 Methods and compositions for stimulating an immune response
WO2020102244A1 (en) 2018-11-14 2020-05-22 Beyondspring Pharmaceuticals, Inc. Methods of treating cancer using tubulin binding agents
CN112778155B (en) 2019-11-11 2023-08-11 大连万春布林医药有限公司 Tucarbaryl derivatives and uses thereof
BR112022022401A2 (en) 2020-05-04 2022-12-13 Beyondspring Pharmaceuticals Inc TRIPLE COMBINATION THERAPY TO INCREASE CANCER CELL KILLING IN CANCER WITH LOW IMMUNOGENICITY

Also Published As

Publication number Publication date
RU2017131430A3 (en) 2019-08-28
AU2016229294B2 (en) 2021-11-04
EP3265090A1 (en) 2018-01-10
US11918574B2 (en) 2024-03-05
MX2017011374A (en) 2018-01-23
WO2016144635A1 (en) 2016-09-15
US20180036304A1 (en) 2018-02-08
CN107530341A (en) 2018-01-02
KR20170131491A (en) 2017-11-29
RU2017131430A (en) 2019-04-09
KR102626155B1 (en) 2024-01-17
US20210275524A1 (en) 2021-09-09
IL254256A0 (en) 2017-10-31
MY190034A (en) 2022-03-22
US10668063B2 (en) 2020-06-02
JP2018507249A (en) 2018-03-15
CN107530341B (en) 2021-10-01
JP6769982B2 (en) 2020-10-14
AU2021290270A1 (en) 2022-01-27
CL2017002241A1 (en) 2018-04-02
HK1250008A1 (en) 2018-11-23
EP3265090A4 (en) 2018-08-01
BR112017018954A2 (en) 2018-05-15
SG11201707127VA (en) 2017-09-28
RU2736045C2 (en) 2020-11-11
US20200289503A1 (en) 2020-09-17
AU2016229294A1 (en) 2017-09-28
CA2978567A1 (en) 2016-09-15
US20190328727A1 (en) 2019-10-31
US11045467B2 (en) 2021-06-29
US10238650B2 (en) 2019-03-26
HK1249052A1 (en) 2018-10-26

Similar Documents

Publication Publication Date Title
HK1249052A1 (en) Method of treating cancer associated with a ras mutation
HK1251408A1 (en) Methods of treating cancer
HK1258098A1 (en) Methods of treating cancer
ZA201804227B (en) Methods of treating cancer
IL254760A (en) Method for treating cancer
IL304252A (en) Method for treating cancer
IL289947A (en) Method for treating cancer
EP3233089A4 (en) Method of treating cancer with cgamp or cgasmp
IL257691A (en) Method for treating cancer
IL262342A (en) Methods of treating cancer
HK1250944A1 (en) Methods for treating cancer
HK1252692A1 (en) Methods of treating or preventing a proteopathy
HK1250942A1 (en) Methods for treating cancer
HK1250943A1 (en) Methods for treating cancer
GB201521886D0 (en) A method of treating a well
GB201510197D0 (en) Method of treating ovarian cancer